ABOUT SIRPIGLENASTAT CLINICAL TRIAL

“This specific prodrug layout manufactured DON focused to its intended location (tumor) and have considerably less of an influence on nutritious cells somewhere else.”It has anticancer consequences by specifically focusing on tumor metabolism and simultaneously inducing a powerful antitumor immune response with immunomodulatory and antineoplast